[New therapeutic approaches in irritable bowel syndrome].
Müller-Lissner
S A
SA
Abteilung für Innere Medizin Park-Klinik Weissensee, Berlin. mueli@park-klinik.com
D002243:Carbolines / Q000009:adverse effects / Q000627:therapeutic use*; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron